We’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Preliminary Experience With Sodium Phenylbutyrate and Taurursodiol in a United States Expanded Access Program
Lead Author: Machelle Manuel, PhD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: October 4 - 6, 2023
Real-World Experience and Strategies to Enhance the Palatability of the Combination Sodium Phenylbutyrate and Taurursodiol for the Treatment of Amyotrophic Lateral Sclerosis
Lead Author: Jamie Timmons, MD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: October 4 - 6, 2023
Update on AMX0114: An Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Jamie Timmons, MD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: October 4 - 6, 2023
Characterization of the Enrolled Population in the Phase 3 PHOENIX Trial in Amyotrophic Lateral Sclerosis: Preliminary Results
Lead Author: Leonard van den Berg (Presenter)
Published: European Network to Cure ALS (ENCALS)
Date: July 12 - 14, 2023
Efficacy of Sodium Phenylbutyrate and Ursodoxicoltaurine Combination in Transgenic Mice Displaying Progressive Motor Neuron Degeneration Phenotype
Lead Author: Jamie Timmons (Presenter)
Published: European Network to Cure ALS (ENCALS)
Date: July 12 - 14, 2023
Effect of an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol on Long-Term Tracheostomy/Ventilation-Free Survival and Hospitalization in Amyotrophic Lateral Sclerosis: Final Results From CENTAUR
Lead Author: Janelle Schafer (Presenter)
Published: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Date: May 6 - 10, 2023
Development and Preclinical Assessment of AMX0114: an Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: Muscular Dystrophy Association (MDA)
Date: March 19 - 22, 2023
Expanded Access to Sodium Phenylbutyrate and Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Updates and Initial Learnings
Lead Author: Sandy Morris, BA, BS, MBA & Philip Green, BS (Presenter)
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022
Independent Expert Review of Cardiac Adverse Events and Electrocardiographic Abnormalities and Parameters in a Phase 2 Trial of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (CENTAUR)
Lead Author: Shide Badri, MD, MPH
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022
Update on an International Phase 3 Trial Evaluating Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (PHOENIX)
Lead Author: Leonard H. van den Berg, MD, PhD
Published: International Symposium on ALS-MND (MNDA)
Date: December 5 - 9, 2022